We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.00 | 29.09% | 17.75 | 17.00 | 18.50 | 18.25 | 15.25 | 16.25 | 7,554,983 | 16:29:58 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Business Services, Nec | 1.04M | -21.69M | -0.0832 | -2.13 | 46.25M |
From May 2022 to May 2024
By Ian Walker
Shares of Angle PLC rose 24% on Wednesday after the company said that the U.S. Food and Drug Administration has cleared its Parsortix system for patients with metastatic breast cancer.
Shares at 1139 GMT were up 24.0 pence at 122.50 pence.
The U.K. liquid-biopsy company's Parsortix system harvests cancer cells from blood for analysis.
"This ground-breaking, first-ever FDA product clearance in metastatic breast cancer provides the platform for Angle to work with our collaborators and customers to support further FDA submissions and the establishment of numerous specific clinical uses across different cancer types," Founder and Chief Executive Andrew Newland said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
May 25, 2022 08:05 ET (12:05 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Angle Chart |
1 Month Angle Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
